AstraZeneca secured exclusive global development and commercial rights to Dizal Pharmaceutical’s marketed EGFR exon 20 insertion lung cancer drug Zegfrovy (sunvozertinib) in a deal valued at up to $1.5 billion, according to company disclosures. The licensing covers expansion into new indications beyond the already approved populations in the US and China.